Clinical Study

Ca209-73L- A Phase 3, Randomized, Open Label Study To Compare Nivolumab Plus Concurrent Chemoradiotherapy (Ccrt) Followed By Nivolumab Plus Ipilimumab Or Nivolumab Plus Ccrt Followed By Nivolumab Vs Ccrt Followed By Durvalumab In Previously Untreated, Loc

Posted Date: Apr 28, 2021

  • Investigator: Emily Daugherty
  • Specialties: Cancer, Lung Cancer, Oncology
  • Type of Study: Drug

The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab (Arm A) vs CCRT followed by durvalumab (Arm C) in participants with untreated Locally Advanced Non-small Cell Lung Cancer.


Locally Advanced Stage Iiia, Iiib, Or Iiic Histologically-Confirmed Nsclc, Ecog 0-1, No History Of Organ Transplant, No Prior Thoracic Radiotherapy, Newly Diagnosed And Treatment-Naïve, No Condition That, In The Opinion Of The Investigator Would Preclude The Patient From Adhering To The Protocol Or Would Increase The Risk Associated With Study Participation


Lung Cancer, Nsclc

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.